title: Gamma-globulin treatment of acute myocarditis in the pediatric population.
abstract: BACKGROUND
  Myocardial damage in myocarditis is mediated, in part, by immunological mechanisms. High-dose intravenous gamma-globulin (IVIG) is an immunomodulatory agent that is beneficial in myocarditis secondary to Kawasaki disease, as well as in murine myocarditis. Since 1990, the routine management of presumed acute myocarditis at Children's Hospital, Boston, and Children's Hospital, Los Angeles, has included administration of high-dose IVIG.
  
  
  RESULTS
  We treated 21 consecutive children presenting with presumed acute myocarditis with IVIG, 2 g/kg, over 24 hours, in addition to anticongestive therapies. A comparison group comprised 25 recent historical control patients meeting identical eligibility criteria but not receiving IVIG therapy. Left ventricular function was assessed during five time intervals: 0 to 7 days, 1 to 3 weeks, 3 weeks to 3 months, 3 to 6 months, and 6 to 12 months. At presentation, the IVIG and non-IVIG groups had comparable left ventricular enlargement and poor fractional shortening. Compared with the non-IVIG group, those treated with IVIG had a smaller mean adjusted left ventricular end-diastolic dimension and higher fractional shortening in the periods from 3 to 6 months (P = .008 and P = .033, respectively) and 6 to 12 months (P = .072 and P = .029, respectively). When adjusting for age, biopsy status, intravenous inotropic agents, and angiotensin-converting enzyme inhibitors, patients treated with IVIG were more likely to achieve normal left ventricular function during the first year after presentation (P = .03). By 1 year after presentation, the probability of survival tended to be higher among IVIG-treated patients (.84 versus .60, P = .069). We observed no adverse effects of IVIG administration.
  
  
  CONCLUSIONS
  These data suggest that use of high-dose IVIG for treatment of acute myocarditis is associated with improved recovery of left ventricular function and with a tendency to better survival during the first year after presentation.
authors.affiliation: Department of Cardiology, Children's Hospital, Boston, Mass. 02115.
authors.forename: N A
authors.initials: NA
authors.lastname: Drucker
authors.forename: S D
authors.initials: SD
authors.lastname: Colan
authors.forename: A B
authors.initials: AB
authors.lastname: Lewis
authors.forename: A S
authors.initials: AS
authors.lastname: Beiser
authors.forename: D L
authors.initials: DL
authors.lastname: Wessel
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: A L
authors.initials: AL
authors.lastname: Baker
authors.forename: A R
authors.initials: AR
authors.lastname: Perez-Atayde
authors.forename: J W
authors.initials: JW
authors.lastname: Newburger
mesh_terms: D000208:Acute Disease; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009205:Myocarditis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D016277:Ventricular Function, Left / Q000502:physiology; D014777:Virus Diseases / Q000453:epidemiology / Q000628:therapy*
chemical_list: D016756:Immunoglobulins, Intravenous